Paul Conyngham has founded a startup named Gamgee, which aims to provide personalized mRNA cancer vaccines for dogs. The initiative stems from his experience with his dog, Rosie, who reportedly benefited from a similar treatment designed using AI tools. Gamgee plans to expand its offerings to include treatments for various diseases across species, including humans.
The startup is backed by Y Combinator and is currently preparing for clinical trials in Australia. While Gamgee claims significant tumor reduction in its first documented case, the science behind the treatment remains complex, and the exact impact of the mRNA vaccine is not definitively established.